It is important for pharmacists to be familiar with the steps that are involved in transitioning oncology therapies that have been historically provided in an inpatient setting to the outpatient setting, and be familiar with the criteria for successful implementation of such an initiative.
While biosimilars and generics are not the same, biosimilars are very likely to adopt the same role in the market over the next decade; however, their safety, efficacy, and general role in the clinical setting remains unclear.
The shift from fee-for-service to value is well underway; there are at least 20 payment reform models currently in existence or proposed for adoption, from payers and/or physician groups.
Facebook
X
LinkedIn
Forward